Death of an endocrinologist and researcher, Fernand Labrie
The endocrinologist and researcher of Quebec Fernand Labrie is no more. The company he founded, Endoceutics, has confirmed to the Sun the news of his death, at the age of 81 years.
Born in Laurierville, on the south shore, in 1937, Dr. Labrie is known for his research in endocrinology, the branch of medicine that deals with hormones. It was founded in 1969 as the Laboratory of molecular endocrinology, one of the largest research groups in endocrinology worldwide. Its work will lead in 1979 to a treatment against prostate cancer and will be the scientific canadian city for 15 years, from 1973 to 1988.
More recently, its medical advances had led to a kind of “female Viagra”, which used to treat certain symptoms of menopause. The Intrarosa, developed for the treatment of dyspareunia (pain during intercourse), graduated in 2016 the green light for marketing in the United States. The following year, the european medicines Agency approved the product, which is not yet available in Canada.
In 2017, the management of Endoceutics began the construction of an industrial complex for $ 80 million in L’ancienne-Lorette. Its commissioning is scheduled for the next month. The drug is currently in production at three plants in Montérégie, in the United States and Mexico.
Dr. Fernand Labrie has also directed the Centre de recherche du CHUL for a little more than 25 years of 1982 and 2008, the department of anatomy and physiology of the faculty of medicine of Laval University between 1990 and 2002.
Last may, the superior Court ordered Dr. Labrie to pay equal shares of the CHU of Québec and Laval University a royalty of $ 11.2 million on the sale of “female Viagra”.
The conviction stems from an agreement reached in 1991 under which Dr. Labrie, then a researcher and professor at the Université Laval, and his company, EndoRecherche, had agreed to pay to the two institutions 25 % of revenue from searches performed on the molecule of DHEA, a hormone-producing.
Dr. Fernand Labrie had also been blamed for negligence by the board of directors of the CHUQ and received four reprimands from the part of the College of physicians following the death, in 1998, Gabriel Lessard, whose prostate cancer had not been detected by the team of researchers led by Dr. Labrie.
Among the many distinctions that Dr. Fernand Labrie has earned during his career, he was made officier of the Ordre national du Québec in 1991, in addition to receiving the prix Armand-Frappier in 2006.
Dr. Labrie died in the night from Wednesday to Thursday in a hospital centre in Quebec, where he had been admitted for an infection, according to a new report by Radio-Canada.
The mayor Régis Labeaume has been to offer its condolences to the family and relatives of the researcher. “The death of Dr. Labrie saddens us deeply, that his life and career are intimately linked to the greater region of Quebec city, where he was a pioneer in the life sciences and one of the pillars of the global hub of research that has become our region,” commented the mayor of Quebec city by way of press release.
The economic development agency Québec international, where Dr. Labrie has served for 14 years, has also paid tribute to a “man of exception” and to emphasize “the priceless legacy” left by the deceased in the middle of the economic capital.
The direction of the CHU de Québec has preferred not to comment on the death of its former chief scientific officer. With Jean-François Cliche